

Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Appendix 3: Deprescribing PPIs in children

Why is the medication prescribed? Does the patient still need to be on treatment?

NICE NG1 & ESPGHAN recommend that after 4 to 8 weeks treatment, a trial off the medication should be attempted.

Consider stopping*/reducing the dose if:

- Indication still unknown
- Started for infant reflux and patient now eating some solids
- Gastro-oesophageal reflux disease (GORD) treated for 4-8 weeks (oesophagitis healed, symptoms controlled)
- Completed Helicobacter pylori eradication (in combination with antibiotics)
- Symptom-free for over 3 months
- Started as cover for NSAID/steroid/antiplatelet which is now stopped
- * If patient has been on omeprazole for >6 months, reduce dose over 2-4 weeks before stopping to reduce risk of rebound symptoms.

Monitor at 2-4 weeks & at 12 weeks for: heartburn, dyspepsia, regurgitation, epigastric pain, loss of appetite, weight loss, and agitation. Advise parents / carers to contact the GP if the symptoms reoccur before the review date.

Recommend reducing the dose

Stop treatment and monitor for return of symptoms.

Treatment **should not be stopped** if the child has been diagnosed with:

- Benign gastric ulcer
 Duodenal ulcers
- On-going, uncontrolled GORD Acid related dyspepsia
- Zollinger-Ellison Syndrome Eosinophilic oesophagitis
- Previous dystonic crises/status dystonicus
 Fat malabsorption despite pancreatic enzyme
- replacement therapy in cystic fibrosis
- Gastro-protection whilst coprescribed a potentially ulcerogenic medicine: NSAID; antiplatelets; anticoagulants; corticosteroids; SSRIs; NSAID + SSRIS and/or aspirin.
- Barrett's oesophagus
- Severe oesophagitis
- History of bleeding GI ulcer

Continue treatment but optimise formulation choice (see above <u>algorithm</u>)

Acknowledgement: NHS Nottingham and Nottinghamshire CCG

Agreed: Area Prescribing Committee: December 2022 Review Date: December 2025